Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Radiation damage and radioprotectants: new concepts in the era of molecular medicine</title><author><name sortKey="Koukourakis, M I" sort="Koukourakis, M I" uniqKey="Koukourakis M" first="M I" last="Koukourakis">M I Koukourakis</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">22294702</idno><idno type="pmc">3486665</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3486665</idno><idno type="RBID">PMC:3486665</idno><idno type="doi">10.1259/bjr/16386034</idno><date when="2012">2012</date><idno type="wicri:Area/Pmc/Corpus">004773</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">004773</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Radiation damage and radioprotectants: new concepts in the era of molecular medicine</title><author><name sortKey="Koukourakis, M I" sort="Koukourakis, M I" uniqKey="Koukourakis M" first="M I" last="Koukourakis">M I Koukourakis</name></author></analytic><series><title level="j">The British Journal of Radiology</title><idno type="ISSN">0007-1285</idno><idno type="eISSN">1748-880X</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Exposure to ionising radiation results in mutagenesis and cell death, and the clinical manifestations depend on the dose and the involved body area. Reducing carcinogenesis in patients treated with radiotherapy, exposed to diagnostic radiation or who are in certain professional groups is mandatory. The prevention or treatment of early and late radiotherapy effects would improve quality of life and increase cancer curability by intensifying therapies. Experimental and clinical data have given rise to new concepts and a large pool of chemical and molecular agents that could be effective in the protection and treatment of radiation damage. To date, amifostine is the only drug recommended as an effective radioprotectant. This review identifies five distinct types of radiation damage (I, cellular depletion; II, reactive gene activation; III, tissue disorganisation; IV, stochastic effects; V, bystander effects) and classifies the radioprotective agents into five relevant categories (A, protectants against all types of radiation effects; B, death pathway modulators; C, blockers of inflammation, chemotaxis and autocrine/paracrine pathways; D, antimutagenic keepers of genomic integrity; E, agents that block bystander effects). The necessity of establishing and funding central committees that guide systematic clinical research into evaluating the novel agents revealed in the era of molecular medicine is stressed.</p></div></front></TEI><pmc article-type="review-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Radiol</journal-id><journal-id journal-id-type="iso-abbrev">Br J Radiol</journal-id><journal-id journal-id-type="hwp">bjradio</journal-id><journal-id journal-id-type="publisher-id">bjr</journal-id><journal-title-group><journal-title>The British Journal of Radiology</journal-title></journal-title-group><issn pub-type="ppub">0007-1285</issn><issn pub-type="epub">1748-880X</issn><publisher><publisher-name>The British Institute of Radiology.</publisher-name><publisher-loc>36 Portland Place, London, W1B 1AT</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22294702</article-id><article-id pub-id-type="pmc">3486665</article-id><article-id pub-id-type="publisher-id">D11058</article-id><article-id pub-id-type="doi">10.1259/bjr/16386034</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Radiation damage and radioprotectants: new concepts in the era of molecular medicine</article-title><alt-title alt-title-type="running-head">Review article: New concepts in radioprotection</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Koukourakis</surname><given-names>M I</given-names></name><degrees>MD</degrees></contrib></contrib-group><aff id="aff1"><addr-line>Department of Radiotherapy and Oncology, Democritus University of Thrace, Alexandroupolis, Greece</addr-line></aff><author-notes><corresp id="cor1">Correspondence: Professor Michael Koukourakis, Department of Radiotherapy and Oncology, Democritus University of Thrace, PO Box 12, Alexandroupolis 68100, Greece. E-mail: <email>targ@her.forthnet.gr</email></corresp></author-notes><pub-date pub-type="ppub"><month>4</month><year>2012</year></pub-date><volume>85</volume><issue>1012</issue><fpage>313</fpage><lpage>330</lpage><history><date date-type="received"><day>9</day><month>1</month><year>2011</year></date><date date-type="rev-recd"><day>12</day><month>2</month><year>2011</year></date><date date-type="accepted"><day>22</day><month>2</month><year>2011</year></date></history><permissions><copyright-statement>© 2012 The British Institute of Radiology</copyright-statement><copyright-year>2012</copyright-year></permissions><abstract><p>Exposure to ionising radiation results in mutagenesis and cell death, and the clinical manifestations depend on the dose and the involved body area. Reducing carcinogenesis in patients treated with radiotherapy, exposed to diagnostic radiation or who are in certain professional groups is mandatory. The prevention or treatment of early and late radiotherapy effects would improve quality of life and increase cancer curability by intensifying therapies. Experimental and clinical data have given rise to new concepts and a large pool of chemical and molecular agents that could be effective in the protection and treatment of radiation damage. To date, amifostine is the only drug recommended as an effective radioprotectant. This review identifies five distinct types of radiation damage (I, cellular depletion; II, reactive gene activation; III, tissue disorganisation; IV, stochastic effects; V, bystander effects) and classifies the radioprotective agents into five relevant categories (A, protectants against all types of radiation effects; B, death pathway modulators; C, blockers of inflammation, chemotaxis and autocrine/paracrine pathways; D, antimutagenic keepers of genomic integrity; E, agents that block bystander effects). The necessity of establishing and funding central committees that guide systematic clinical research into evaluating the novel agents revealed in the era of molecular medicine is stressed.</p></abstract></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004773 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 004773 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.31. |  |